syndesi therapeutics ceo

Find contact info for Syndesi Therapeutics SA employees. million verified professionals across 35 million companies. free lookups / month. All rights reservedLast updated on:January, 28, 2022, Syndesi Therapeutics is based in Belgium and will leverage UCBs neurology expertise in modulating the synaptic vesicle protein SV2A. Unlike, UCB is the world leader in SV2A research, having discovered and developed two major anti-epileptic drugs treating patients around the world. AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease . Region: Europe. Contact Information Website www.syndesitherapeutics.com Ownership Status Acquired/Merged Financing Status Formerly VC-backed Primary Industry Drug Discovery Other Industries Biotechnology Acquirer AbbVie Primary Office Chemin du Cyclotron 6 1348 Ottignies-Louvain-la-Neuve Belgium +32 010 00 00 00 Want detailed data on 3M+ companies? . All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. Founded in 1973, JJDC continues a legacy of customizing deals for data-driven companies across the continuum of healthcare, with the goal of turning great ideas into transformative new pharmaceutical, medical device and consumer healthcare products. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. Name of the organization that made the acquisition, Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Syndesi Therapeutics has been formed by UCB and a group of investors, including Novo Seeds and V-Bio to develop a group of compounds for cognitive disorders caused by diseases like Alzheimer's. Syndesi Therapeutics will use of Belgian biotech UCB's expertise in drug discovery for neurological conditions to . Lorem ipsum dolor sit, amet consectetur adipisicing elit. Up to 5 Syndesi Therapeutics is in the sectors of: Biotechnology. Regulating synaptic transmission represents a promising . The company is the holding company in the Novo Group, comprising Novo Nordisk A/S, Novozymes A/S and NNIT A/S, and is responsible for managing the Foundations assets. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by . Jonathan Savidge, Chief Executive Officer, Syndesi Therapeutics, said: "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases. All rights reserved. Enter employee name to find & verify emails, phones, social links, etc. Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, provides an update on the clinical development of its lead molecule, SDI-118, and announces an extension of its series A financing. Jonathan Savidges role in Syndesi Therapeutics is CEO, Jonathan Savidges business email address is ****@syndesitherapeutics.com, Jonathan Savidges HQ phone number is ********. 2007 -2022 UCB S.A., Belgium. jonathan savidge, phd ceo of syndesi noted "development of these small molecules that modulate the sv2a target in a distinct manner represents an intriguing new approach for the treatment of cognitive deficits since they specifically target synaptic dysfunction, a hallmark of alzheimer's disease and other indications characterized by cognitive Enter your email to download the profile. With an upfront payment of $130 million, AbbVie gains Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI 118. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. {{ userNotificationState.getAlertCount('bell') }}. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Syndesi Therapeutics. Chief Executive Officer and Technical Lead, Associate Director, Asia Pacific Logistics. Lorem ipsum dolor sit amet consectetur adipisicing elit. Sign up for a free account. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. The objective of the fund is to invest in the development of start-ups, from validation of the technology to commercial maturity. Syndesi Therapeutics is developing molecules that modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement. See more information about Jonathan Savidge. Syndesi benefits both from UCBs research expertise and from an impressive syndicate of experienced investors and their respective networks., Cognitive impairment remains an area of significant unmet need for patients not only with Alzheimers Disease but also more broadly across a range of neurological disorders, and we are excited about the potential promise of this novel therapeutic approach, says Morten Graugaard Dssing, Principal at Novo Seeds. Get Contact Info for All Departments Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). No credit card required. About Bone Therapeutics Back to companies Company name Syndesi Therapeutics Location Louvain-la-neuve Belgium CEO Jonathan Savidge Website Its current portfolio fair value is above 150 million . View contacts for Syndesi Therapeutics to access new leads and connect with decision-makers. March 01, 2022. The funds (VIVES I - 15 million and VIVES II - 43 million) are managed by SOPARTEC, UCLs technology transfer company, member of the Louvain Technology Transfer Office. I am thrilled to be working with the company which is supported by scientists at UCB and able to leverage Janssen neuroscience expertise via a presence at the JLINX incubator, all in an effort to develop products that could one day make a meaningful difference for patients suffering from cognitive impairment.. Founding CEO at Syndesi Therapeutics (now an AbbVie Company) Greater Oxford Area 1K followers 500+ connections Join to connect AbbVie The University of Manchester About - 20 years of. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Find contact info for Syndesi Therapeutics SA employees. Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment seen in multiple CNS disorders, including Alzheimers Disease, schizophrenia and depresson. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Alzheimer's Therapeutics Research Leader Dr. Roy Twyman Joins NeuroVision Imaging Board Twyman Served as Senior Vice President at Janssen Pharmaceutical Research & Development, Overseeing . Jonathan Savidge, PhD CEO of Syndesi noted: "Development of these small molecules that modulate the SV2A target in a distinct manner represents an intriguing new approach for the treatment of . Up to 5 San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. AbbVie will pay Syndesi's shareholders a $130 million upfront payment with the potential for Syndesi's shareholders to receive additional contingent payments of up to $870 million based on the achievement of certain predetermined milestones. Regulating the synaptic transmission is a promising approach to treat Alzheimer's disease and other disorders with cognitive impairment. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. Syndesi Therapeutics awarded non-dilutive funding of up to 3.2M for development of its lead program, SDI-118, aimed at treating cognitive impairment Belgium - 20 March 2019 - Syndesi Therapeutics SA, a biotechnology company . Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Show more Syndesi Therapeutics headquarters is in Louvain-la-Neuve, Walloon Region. ABBV ie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand ABBV ie's neuroscience portfolio. Johnson & Johnson Innovation JJDC Inc. (JJDC) is the strategic venture capital arm of Johnson & Johnson and a long-term investment partner to global healthcare entrepreneurs. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research. We are excited to see Syndesi develop our novel pro-cognitive SV2A modulators to create value for patients with cognitive impairment, said Dhavalkumar Patel, UCBs Chief Scientific Officer and Executive Vice President. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations. Fountains main office is in Dublin, Ireland, with a second office in New York. A regenerative therapy company - Bone Therapeutics Bone Therapeutics is an advanced biotechnology company with a unique approach to the development of cell therapy products for orthopaedics and bone diseases. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the worlds premier life science institutes. Novo Seeds is the early-stage investment arm of Novo Holdings (www.novoholdings.dk). Type Private Founded 2018 HQ Syndesi Therapeutics (www.syndesitherapeutics.com) has been established at the Centre dEntreprises et dInnovation (CEI) in Louvain-la-Neuve and will have a presence at the JLINX incubator facilities to access expertise at the Janssen campus in Beerse, Belgium. According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. Active, Closed, Last funding round type (e.g. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic . I am delighted with the announcement of this deal. Regulating synaptic transmission represents a . Jonathan Savidges email address is ****@syndesitherapeutics.com, Jonathan Savidges direct phone number is ********. 01 Mar 2022. Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio. Novo Holdings is a private limited liability company wholly owned by the Novo Nordisk Foundation. The Belgian life science ecosystem is particularly vibrant and we realised that it was the right environment to promote this research as part of our biotech model approach., Jonathan Savidge, PhD CEO of Syndesi noted Development of these small molecules that modulate the SV2A target in a distinct manner represents an intriguing new approach for the treatment of cognitive deficits since they specifically target synaptic dysfunction, a hallmark of Alzheimers Disease and other indications characterized by cognitive impairment. UCB is listed on Euronext Brussels (symbol: UCB). read more 10 Dec Get contact details including emails and phone numbers million verified professionals across 35 million companies. UCB spins out neuro startup with 17M from Novo, Johnson & Johnson Syndesi Therapeutics. Driven by science. You'll receive an email shortly. Clinical studies at UCB: How are medicines made and tested? Jonathan Savidge colleagues are Steven Ramael,John Kemp. Syndesi Therapeutics | 837 followers on LinkedIn. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. Regulating synaptic transmission represents a promising approach to treating Alzheimers Disease and other disorders with cognitive impairment. Prior to teaming up with Droia, Luc was the CEO of Tusk Therapeutics from 2015 until it was sold to Roche in 2018. There is a major unmet need for new therapies that can . Jonathan Savidge Chief Executive Officer John Kemp Chief Scientific Officer Torsten Madsen Chief Medical Officer Maeve Duffy Head of Clinical Operations Steven Ramael Medical Director Jean Combalbert After the IPO of iTeos Therapeutics last year, Syndesi represents the second potential unicorn of VIVES Fund. Search over 700 Sign up for a free account. About Syndesi Therapeutics. Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions. Within the life science sector, specific areas of interest to Fountain include specialty pharma, medical devices, biotechnology and diagnostics. www.jjdc.com. Syndesi has an exclusive, worldwide license from UCB to develop and commercialise a series of novel, pro-cognitive SV2A modulators. Led by Jonathan Savidge, PhD, CEO, Syndesi Therapeutics has an exclusive, worldwide license from UCB to develop and commercialize a series of novel, procognitive SV2A modulators to improve . Address: Centre d'Entreprises et d'Innovation (CEI) Incubator Chemin du Cyclotron 6 1348 Louvain-la-Neuve Belgium. Enter employee name to find & verify emails, phones, social links, etc. Company profile page for Syndesi Therapeutics SA including stock price, company news, press releases, executives, board members, and contact information If you have any question, email us support@arounddeal.com. V-Bio Ventures (www.v-bio.ventures) is an independent venture capital firm specialized in building and financing young, innovative life science companies. Jonathan Savidge is the CEO at Syndesi Therapeutics based in United Kingdom. VIVES II is funded by a dozen leading Belgian and European investors such as the EUROPEAN INVESTMENT FUND (EIF), SFPI-FPIM, BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM, BPI FRANCE (France), ING BELGIUM, SOFINA, AXA BELGIUM, BELFIUS, IRD (France), NIVELINVEST, REGION BRUXELLES CAPITAL and by SOPARTEC. After the sale of Tusk, he joined Droia initially as Venture Partner and then as Partner in the Oncology II Fund. This acquisition gives . Find More Contacts for Syndesi Therapeutics, Edit Lists Featuring This Company Section, Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie, Syndesi Therapeutics Announces Positive Results From Two Additional Phase I Studies Of Its Novel SV2A modulator SDI-118. Jonathan Savidge works for Syndesi Therapeutics. Lorem ipsum dolor sit amet consectetur adipisicing elit. Developing novel SV2A modulators as potential treatments for cognitive impairment | Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Syndesi Therapeutics's Chief Executive Officer is Jonathan Savidge. In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Jonathan Savidge CEO Torsten M. Madsen Chief Medical Officer Board Member and Advisor Profiles Number of Board Member and Advisor Profiles 2 Syndesi Therapeutics has 2 board members and advisors, including Morten Graugaard Dssing. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Philippe Durieux, CEO of Sopartec, the management company of VIVES: "The acquisition of Syndesi by Abbvie illustrates our ability of creating bridges between science and industry. UCB and investor syndicate led by Novo Seeds launch Syndesi Therapeutics to develop novel therapeutics for cognitive disorders, 2007 - 2022UCB S.A., Belgium. Follow us on Twitter: @UCB_news. They are also entitled to get further contingent payments of up to $870m on meeting specific pre-set milestones. Disclosure of payments to Healthcare Professionals. Contact Email info@syndesitherapeutics.com Phone Number +32 10 280 238 Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). We are creating a new and unique treatment approach using differentiated bone-forming cells. {{ userNotificationState.getAlertCount('bell') }}. Sharing his thoughts on the deal, Tom Hudson, senior vice president, R&D, chief scientific officer, AbbVie, said: "There is a major unmet need for new therapies that can help improve cognitive function in . If you have any question, email us support@arounddeal.com. Novo Holdings A/S (formerly Novo A/S) is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S.Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation's assets, which in 2021 was worth almost DKK 700 billion Danish Kroner (approximately US$93.73 billion) and is the largest charitable foundation in the world making Novo . About Syndesi Therapeutics. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the bra. The mechanism is currently being evaluated for . The VIVES Louvain Technology Fund (www.vivesfund.com) is a multi-sector technology fund which invests in the spin-offs of the Universit catholique de Louvain (UCL) and start-ups in Belgium and neighboring countries. T+32.2.559.9588, isabelle.ghellynck@ucb.com. SRIW facilitates the region's economic development, contributing effectively to the modernisation, growth and restructuring of the businesses that make up the Walloon industrial network. Syndesi will build on a rich legacy of work by UCB to further develop these novel SV2A modulators to investigate their potential to improve cognition in diseases such as Alzheimers Disease, other dementias and cognitive impairment associated with schizophrenia. Syndesi Therapeutics's key executives include Jonathan Savidge and 6 others. Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, today announced Torsten Madsen MD, PhD has joined its management team as Chief Medical Officer. There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved.

Lenovo Laptop Case 14-inch, Best Title For Farmers, Airstream Basecamp Awning Setup, Alcohol-induced Thrombocytopenia, Njcu School Of Business Map, Ordos China Ghost Town, Edit Dicom Tags Microdicom, Pga Senior Tour Qualifying, Princess Gloria Makeup Salon, Ecs Cloudformation Deployment,